The transformation from adenocarcinoma to small cell lung cancer (SCLC) and squamous cell carcinoma (SCC) has been described after treatment with third-generation EGFR-TKIs like osimertinib as first-line or second-line [49–52]. This evidence concerns the gene EGFR and small cell lung carcinoma.